Clinical trial
A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation
NCT02642614 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 25, 2016
- Completion date
- June 14, 2016
- Enrollment
- 120 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.